MPR Weekly Dose Podcast

New vaccine to prevent lower respiratory tract disease; A new treatment for heart failure; Concerns over compounded semaglutide; New extended-release opioid use disorder treatment; Treatment for motion sickness shows promise.

First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; Nasal spray for opioid overdoses; Child cough suppressant recalled.

FDA requires label updates for the entire class of prescription stimulants; Novel treatment approved for menopause symptoms; FDA Committee takes votes on potentially accelerated approval of Duchenne muscular dystrophy gene therapy; Fungal meningitis outbreak in US; Wearable child thermometer recalled.

Panel votes unanimously in favor of an over-the-counter change for contraceptive pill; First pharmacological therapy for agitation associated with dementia due to Alzheimer disease; Elfabrio approved for the treatment of Fabry disease; Farxiga approval expanded; Bacterial contamination concerns for certain COVID-19 at-home tests.

Investigational treatment for early Alzheimer disease shows promise; First vaccine for the prevention of lower respiratory tract disease caused by RSV; Nightly granules approved for narcolepsy; Latest health tech advance in toilets; And FDA warns of energy boosting over-the-counter inhalants.

Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.

Updates to COVID-19 vaccines; FDA panel votes on potential treatment for agitation with Alzheimer dementia; DEA deschedules drug; Migraine treatment indication expanded; A new device is cleared to aid in restless legs syndrome.

Implantable device approved to for knee osteoarthritis; Prescribing Information labelling updated for opioids; Imbruvica has indications withdrawn; Patch to combat excessive underarm sweating given green light; Novel treatment Fast Tracked for Type A and B influenza.

Treatment granted Emergency Use Authorization for hospitalized COVID-19 patients; Preterm-birth prevention treatment withdrawn from market; Sleep device for infants gets green light for marketing; New Padcev plus Keytruda indication; Mail-back system for unused opioids; Opioid overdose prevention device approved.

Two diabetes drugs permanently discontinued; Consistent reduction in schizophrenia symptoms found with an investigational Tx; Positive results for investigational social anxiety disorder therapy; High-concentration Humira biosimilar approved; Sleep apnea treatment expanded for pediatrics with Down syndrome.